1.
Statins: a new approach to combat temozolomide chemoresistance in glioblastoma.
Shojaei, S, Alizadeh, J, Thliveris, J, Koleini, N, Kardami, E, Hatch, GM, Xu, F, Hombach-Klonisch, S, Klonisch, T, Ghavami, S
Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2018;(8):1083-1087
Abstract
Patients with glioblastoma multiforme (GBM) have an average life expectancy of approximately 15 months. Recently, statins have emerged as a potential adjuvant cancer therapy due to their ability to inhibit cell proliferation and induce apoptosis in many types of cancer. The exact mechanisms that mediate the inhibitory actions of statins in cancer cells are largely unknown. The purpose of this proceeding paper is to discuss some of the known anticancer effects of statins, while focusing on GBM therapy that includes adjunct therapy of statins with chemotherapeutic agents.